Formation cross-sections and chromatographic separation of protactinium isotopes formed in proton-irradiated thorium metal

Radchenko, Valery; Engle, Jonathan W.; Wilson, Justin J.; Maassen, Joel R.; Nortier, F.M.; Birnbaum, Eva R.; John, Kevin D.; Fassbender, Michael E.

doi:10.1515/ract-2015-2486

Cited by 28 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This strategy has been further improved by additional steps for the co-extraction of other valuable medical radionuclides - including 225, 224, 223 Ra, 230 Pa, 103 Ru and 111 Ag - without disturbing the actinium purification process [70].…”

Section: Radiochemical Isolation Of 225acmentioning

confidence: 99%

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Robertson

Ramogida

Schaffer

et al. 2018

CRP

Self Cite

149

113

View full text Add to dashboard Cite

show abstract

Section: Radiochemical Isolation Of 225acmentioning

confidence: 99%

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Robertson

Ramogida

Schaffer

et al. 2018

CRP

Self Cite

149

113

View full text Add to dashboard Cite

show abstract

“…The mobile phase was composed of 0.1% formic acid in KH 2 PO 4 in water (A) and 0.1% formic acid in acetonitrile (B) in the ratio of 70:30 (v/v) throughout the analysis. 10 The selected detection wavelengths for methylprednisolone sodium succinate and tropisetron were 245 and 285 nm, respectively. 11…”

Section: Chromatographic Conditionsmentioning

confidence: 99%

Compatible stability of methylprednisolone sodium succinate and tropisetron in 0.9% sodium chloride injection

Chen

Lei

2018

Eur J Hosp Pharm

View full text Add to dashboard Cite

background A combination of methylprednisolone sodium succinate and tropisetron hydrochloride is commonly used to treat the nausea and vomiting associated with antineoplastic therapy. The objective of this study was to investigate the stability of tropisetron hydrochloride and methylprednisolone sodium succinate in 0.9% sodium chloride injection for up to 48 hours. Methods Commercial solutions of methylprednisolone sodium succinate and tropisetron hydrochloride were obtained and further diluted with 0.9% sodium chloride injection to final concentrations of either 0.4 or 0.8 mg/ mL (methylprednisolone sodium succinate) and 0.05 mg/ mL (tropisetron). The admixtures were assessed for periods of up to 48 hours after storage at 4°C with protection from light and at 25°C without protection from light. Physical compatibility was determined visually, and the chemical compatibility was measured with high-performance liquid chromatography (HPLC) and by measurement of pH values. results HPLC analysis demonstrated that methylprednisolone sodium succinate and tropisetron hydrochloride in the various solutions were maintained at 97% of the initial concentrations or higher during the testing period. There were no changes observed by physical precipitation or pH in any of the prepared solutions. Conclusions Tropisetron hydrochloride injection and methylprednisolone sodium succinate injection in 0.9% sodium chloride injection are stable for up to 48 hours at 4°C and 25°C.Original research combination of 0.05 mg/mL tropisetron and 0.4-0.8 mg/mL methylprednisolone sodium succinate, prepared in 0.9% sodium chloride injection and stored in polyolefin bags, was chemically stable for at least 48 hours at 4°C and 25°C.Contributors CP and JXL conceived and designed the experiments. CP performed the experiments. CP and JXL analysed the data. CP wrote the paper.

show abstract

“…The calculated yield of 225 Ac by the 226 Ra(p,2n) 225 Ac reaction over E p = 22 → 10 MeV amounts to 7 MBq/μA·h and that via the spallation process over E p = 140 → 60 MeV to 4 MBq/μA·h . Both of the latter accelerator methods of production require further experimental work, particularly with regard to the determination of impurities …”

Section: Novel Radionuclides For Internal Radiotherapymentioning

confidence: 99%

“…134,135 Both of the latter accelerator methods of production require further experimental work, particularly with regard to the determination of impurities. 138,139 3.4 | 117m Sn (T ½ = 13.6 d)…”

Section: Ac (T ½ = 100 D)mentioning

confidence: 99%

Development of novel radionuclides for medical applications

Qaim

Spahn

2017

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Medical radionuclide production technology is well established. There is, however, a constant need for further development of radionuclides. The present efforts are mainly devoted to nonstandard positron emitters (eg, Cu, Y, I, and Se) and novel therapeutic radionuclides emitting low-range β particles (eg, Cu and Re), conversion or Auger electrons (eg, Sn and Br), and α particles (eg, Ac). A brief account of various aspects of development work (ie, nuclear data, targetry, chemical processing, and quality control) is given. For each radionuclide under consideration, the status of technology for clinical scale production is discussed. The increasing need of intermediate-energy multiple-particle accelerating cyclotrons is pointed out.

show abstract

Formation cross-sections and chromatographic separation of protactinium isotopes formed in proton-irradiated thorium metal

Abstract: Targeted alpha therapy (TAT) is a treatment method of increasing interest to the clinical oncology community that utilizes

Cited by 28 publications

References 0 publications

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Compatible stability of methylprednisolone sodium succinate and tropisetron in 0.9% sodium chloride injection

Development of novel radionuclides for medical applications

Contact Info

Product

Resources

About

Formation cross-sections and chromatographic separation of protactinium isotopes formed in proton-irradiated thorium metal

Abstract: Targeted alpha therapy (TAT) is a treatment method of increasing interest to the clinical oncology community that utilizes

Cited by 28 publications

References 0 publications

Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Compatible stability of methylprednisolone sodium succinate and tropisetron in 0.9% sodium chloride injection

Development of novel radionuclides for medical applications

Contact Info

Product

Resources

About

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences